Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Sponsor
Istituto Oncologico Veneto IRCCS
Study ID
NCT04416646
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.

Study Details

The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.

Key Dates

Start date
Feb 27, 2019
Status verified
Apr 2026
Primary completion
Jun 26, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
100 participants (actual)

Primary Outcome Measure

Clinical tolerability of Cabozantinib [ Time Frame: Average of 1 year ]

Related Studies